Research programme: monoamine oxidase B inhibitors - Dart NeuroScience

Drug Profile

Research programme: monoamine oxidase B inhibitors - Dart NeuroScience

Latest Information Update: 03 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Helicon Therapeutics
  • Developer Dart NeuroScience
  • Class Isoxazoles
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurodegenerative disorders

Most Recent Events

  • 03 Dec 2015 Discontinued for Neurodegenerative disorders in USA (unspecified route)
  • 13 Apr 2015 Early research in Neurodegenerative disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top